lung cancer
Conditions
Interventions
A:Avastin
B:Docetaxel
Sponsors
Yin Yi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients were eligible for this phase II trialin the event that they were either cytologically or histologically confrmed to have NSCLC; were in stage IV; had measurable disease; received at least 2 prior treatments; were in the age range of 20-74 years; had an Eastern CooperativeOncology Group (ECOG) performance status of 0 or 1; and had a projected life expectancy of at least 3 months. Other eligibility criteria for organ function included: leukocyte count 4000-12,000/ul, absolute granulocyte count =2000/ul, platelet count =100,000/ul, hemoglobin level =9 g/dl, serum bilirubin level =1.5 mg/dl, serum aspartate aminotransferase and alanine amino transferase levels =100 IU/l, alkaline phosphatase level of twice the upper limit or less, normal creatinine level, creatinine clearance rate of =60 ml/min,and arterial oxygen partial pressure of =60 Torr.
Exclusion criteria
Exclusion criteria: Exclusion criteria included pregnancy or serious concomitant disease, concomitant malignancy, symptomatic symptomatic cerebral involvement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR; | — |
Countries
China
Contacts
Public ContactYin Yi
Fujian Cancer Hospital
Outcome results
None listed